Fig. 5: Biocompatibility and wound healing efficacy of FgC6 patch.

a Schematic of implanting FgC6 patch on the liver incision injury in the rat model. b Rat liver collected at 1, 2, 4 weeks post-sealing with the FgC6 patch. c Degradation rate of subcutaneously implanted FgC6 patch (n = 3 biologically independent replicates). d Representative histology images stained with H&E for Surgicel® Fibrillar at 2 weeks, and FgC6 patch at 2, 4 weeks after haemostatic treatment. The experiment was repeated three times independently with similar results for d. e Representative immunofluorescence images for Surgicel® Fibrillar at 2 weeks, and FgC6 patch at 2, 4 weeks after haemostatic treatment. The experiment was repeated three times independently with similar results for e. Fluorescence intensity was measured from the immunofluorescence images of the Surgicel® Fibrillar and FgC6 patch group for f CD68 (n = 3 biologically independent replicates) and g CD206 makers (n = 3 biologically independent replicates). Cell nuclei were stained with DAPI (blue). Green fluorescence represented the expression of CD68 or CD206. h Complete blood counts (CBCs) of control (healthy rats) and rats with the implanted FgC6 patch at 1, 2, 4 weeks (n = 3 biologically independent rats). i Blood chemistry of control group (healthy rats) and FgC6 patch group at 1, 2, 4 weeks (n = 3 biologically independent rats). Error bars, mean ± SD. P values are determined by a two-sided Student’s t-test for f and g. ns, not significant.